摘要
目的通过观察玛咖不同提取物和单体对小鼠的免疫调节作用,探讨其对小鼠脾淋巴细胞增殖及诱生白细胞介素-2(IL-2)和肿瘤坏死因子-α(TNF-α)的影响。方法用反相硅胶柱(ODS柱)将玛咖甲醇提取物进行分段富集,获得Fr_(1),Fr_(2),Fr_(3),Fr_(4),Fr_(5)和Fr_(6)6个部位及3个单体。设置玛咖不同提取物和单体的不同给药剂量组,采用细胞增殖与活性检测法(CCK-8)检测其对无丝裂原组、刀豆蛋白A(Con A)诱导组、脂多糖(LPS)诱导组模型小鼠脾淋巴细胞增殖的影响,采用酶联免疫吸附测定试验法(ELISA)测定IL-2和TNF-α的含量。结果与模型组比较,玛咖提取物Fr_(3),Fr_(6),单体N-苄基十六碳酰胺和1,2-二氢-4-甲醛-3-苯甲基-N-羟基吡啶对Con A诱导的T淋巴细胞和LPS诱导的B淋巴细胞存在一定促进增殖作用(P<0.01),增殖作用较弱,玛咖提取物和单体能显著诱导脾淋巴细胞分泌IL-2和TNF-α(P<0.01)。结论玛咖提取物及单体能够通过增强IL-2和TNF-α的分泌发挥免疫增强作用,同时可以一定程度上促进脾淋巴细胞的增殖。作用药效物质基础推测可能是玛咖酰胺和吡啶类生物碱,具体作用机制仍需进一步探讨。
Objective To explore effects of different extracts and monomers of Lepidium meyenii(Maca)on the proliferation of mouse splenic lymphocytes and induction of interleukin-2(IL-2)and tumor necrosis factor-α(TNF-α)by observing their immunomodulatory effects.Method An octadecylsilyl(ODS)column was used to enrich the methanol extract of L.meyenii in stages to obtain six fractions and three monomers.Different groups of extracts and monomers of L.meyeniiat different doses were set up.Cell counting Kit-8(CCK-8)was used to detect the effect on the proliferation of mitogen-free,concanavalin A(Con A)-induced,and lipopolysaccharides(LPS)-induced mouse splenic lymphocytes.Enzyme-linked immunosorbent assay(ELISA)was used to determine the levels of IL-2 and TNF-α.Result L.meyeniiextracts Fr3 and Fr6,and monomers N-benzyl hexadecanamide and 1,2-dihydro-4-carboxaldehyde-3-benzyl-N-hydroxypyridine slightly promoted the proliferation of Con A-induced T lymphocytes and LPS-induced B lymphocytes(P<0.01)as compared with the conditions in the model group.L.meyenii extracts and monomers significantly induced the secretion of IL-2 and TNF-αby splenic lymphocytes(P<0.01).Conclusion L.meyenii extracts and monomers can achieve immunological enhancement by promoting the secretion of IL-2 and TNF-α,and facilitate the proliferation of splenic lymphocytes.The active components are presumedly macamides and pyridine alkaloids,and the specific mechanism still needs to be further explored.
作者
李明利
边宝林
王宏洁
司南
魏晓露
赵海誉
周严严
LI Ming-li;BIAN Bao-lin;WANG Hong-jie;SI Nan;WEIXiao-lu;ZHAO Hai-yu;ZHOU Yan-yan(Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences,Beijing 100700,China)
出处
《中国实验方剂学杂志》
CAS
CSCD
北大核心
2021年第23期97-103,共7页
Chinese Journal of Experimental Traditional Medical Formulae
基金
国家“重大新药创制”科技重大专项(2019ZX09201005-006-002)
中国中医科学院2017年度中医药“一带一路”合作专项(GH2017-03-01)。
